The osteocyte as a therapeutic target in the treatment of osteoporosis - Wikidata - wikimedia - TriplyDB

The osteocyte as a therapeutic target in the treatment of osteoporosis

The osteocyte as a therapeutic target in the treatment of osteoporosis

http://www.wikidata.org/entity/Q27009129

about

Modalities for Visualization of Cortical Bone Remodeling: The Past, Present, and Future Cancer Cell Colonisation in the Bone Microenvironment CORR Insights®: fractures in geriatric mice show decreased callus expansion and bone volume Perspectives on osteoporosis therapies.New Target Sites for Treatment of Osteoporosis.Strategies Developed to Induce, Direct, and Potentiate Bone Healing.Ex vivo replication of phenotypic functions of osteocytes through biomimetic 3D bone tissue construction.

P2860

Q26796206-451359AF-27C3-4AB9-82F1-B137FE5F59E0 Q28072561-9084F735-D162-4319-8139-62C04AA3896A Q34276870-BCB9C699-23C0-4953-AA80-B4891570B85B Q38313739-0308A61B-DFAA-490B-94C9-467907FAB9E9 Q39151180-27A16C93-1B25-4AA6-B0F4-50598D589777 Q46141908-8F32154A-060B-4805-8EB2-C68BCBD06298 Q47413986-737E45BA-37B5-448D-BB90-AE2FBF75E0AF

P2860

The osteocyte as a therapeutic target in the treatment of osteoporosis

http://www.wikidata.org/entity/Q27009129

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

The osteocyte as a therapeutic target in the treatment of osteoporosis

@ast

The osteocyte as a therapeutic target in the treatment of osteoporosis

@en

The osteocyte as a therapeutic target in the treatment of osteoporosis

@nl

type

label

The osteocyte as a therapeutic target in the treatment of osteoporosis

@ast

The osteocyte as a therapeutic target in the treatment of osteoporosis

@en

The osteocyte as a therapeutic target in the treatment of osteoporosis

@nl

prefLabel

The osteocyte as a therapeutic target in the treatment of osteoporosis

@ast

The osteocyte as a therapeutic target in the treatment of osteoporosis

@en

The osteocyte as a therapeutic target in the treatment of osteoporosis

@nl

P1433

Q27009129-35414D46-E074-44AD-A9AA-72BCE70F4AF5

P1476

Q27009129-B18CEAB9-591F-47B1-9F4E-0D702EFD1D88

P2860

Q27009129-0057EF71-6DC0-426C-A33E-B50B911E6F12

Q27009129-03EDB1F1-0BB0-4804-99F9-1FE607A94FFC

Q27009129-0A529088-A6FA-4CD1-B495-6F86A02C7713

Q27009129-0C91437B-A9B2-4F36-B50E-4E0A86AA7CF9

Q27009129-0E8F142C-5133-4A6A-9F5C-D83235837BAB

Q27009129-14524628-B492-4569-8D4E-DC9EB53E7123

Q27009129-18234CDD-4996-4498-8BB5-96C42B6CBF06

Q27009129-188346C9-49C5-4A06-AC93-84EACDC37569

Q27009129-1BCF5ED8-6969-4984-A2E8-80FF328F77A4

Q27009129-1C5C51AB-20B9-4D85-9E05-53EE946E11A2

P304

Q27009129-B652EFB3-514F-4690-9014-68439E8B173A

P31

Q27009129-9BA2BFD1-FB8F-4966-B01E-C29C4FEA103F

P3181

Q27009129-0D9FC8C5-D213-4535-9BED-726CB964FEC5

P356

Q27009129-16B2A1CD-0129-40F0-BC38-9BFEA50AE16E

P407

Q27009129-72A21F26-B5DF-4BCB-88E2-68D07ABC6DAF

P433

Q27009129-19D1D027-B208-48F3-91F2-CD00C339A620

P478

Q27009129-681B9F0B-279E-45D2-80E6-23289F2C9E2D

P50

Q27009129-E47FC5B9-B13D-497B-95D0-C4887EEC1E7E

P577

Q27009129-797976FE-219D-4387-85E5-C1010B55FE3E

P5875

Q27009129-16488EC6-5E7D-4943-A13F-DEC5D9C784E5

P698

Q27009129-173F99B7-B79D-4447-8E2C-34ABC57A330C

P921

Q27009129-5389593E-DE87-4913-B0AD-A29FA46F974B

P932

Q27009129-3A37F106-BF6B-4637-95FD-B32558470DB2

P3181

P356

1759720X14523500

P1433

Therapeutic advances in musculoskeletal disease

P1476

The osteocyte as a therapeutic target in the treatment of osteoporosis

@en

P2860

Development of bisphosphonates.

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

LRP4 mutations alter Wnt/beta-catenin signaling and cause limb and kidney malformations in Cenani-Lenz syndrome

Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites.

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

Effects of PTH on osteocyte function

The amazing osteocyte

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist

P304

79-91

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3146573

http://www.w3.org/2001/XMLSchema#string

P356

10.1177/1759720X14523500

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Gaël Y. Rochefort

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262816736

http://www.w3.org/2001/XMLSchema#string

P698

24891879

http://www.w3.org/2001/XMLSchema#string

P921

P932

4040939

http://www.w3.org/2001/XMLSchema#string